The latest update is out from Alphamab Oncology ( (HK:9966) ).
Alphamab Oncology reported significant financial growth for the year ended December 31, 2024, with a substantial increase in revenue and a return to profitability. The company achieved several key milestones, including the registration of Envafolimab in Macau and a licensing agreement for its oncology drug KN035 with Glenmark. Additionally, Alphamab made notable advancements in clinical trials for its drugs KN046 and Envafolimab, which were recognized in prestigious scientific journals and guidelines, enhancing its position in the oncology market.
More about Alphamab Oncology
Alphamab Oncology is a biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. The company specializes in antibody-based therapeutics and has a strong emphasis on research and development to advance its drug pipeline.
YTD Price Performance: 112.29%
Average Trading Volume: 5,084,733
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.14B
See more insights into 9966 stock on TipRanks’ Stock Analysis page.